Supernus Pharmaceuticals (LTS:0LB2) Long-Term Debt: $0.0 Mil (As of Mar. 2026)


LTS:0LB2 Supernus Pharmaceuticals Inc LTS:0LB2
88 GF Score
Price $48.27
GF Value $41.04
Valuation Modestly Overvalued
View Full Analysis

What is Supernus Pharmaceuticals Long-Term Debt?

Supernus Pharmaceuticals LTS:0LB2 +0.60% 88 Long-Term Debt is $0.0 Mil as of Mar. 2026. GuruFocus rates LTS:0LB2 with a GF Score™ of 88/100 and a GF Value™ of $41.04 (Modestly Overvalued).

Supernus Pharmaceuticals's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.0 Mil.

Supernus Pharmaceuticals  (LTS:0LB2) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Supernus Pharmaceuticals Long-Term Debt Related Terms

Supernus Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Supernus Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals Long-Term Debt Chart

Supernus Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 379.25 0.00 0.00 0.00 0.00

Supernus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0LB2
88GF Score
Supernus Pharmaceuticals Inc LTS:0LB2
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.0 Mil mean?
Supernus Pharmaceuticals (LTS:0LB2) has a Long-Term Debt of $0.0 Mil as of Mar. 2026.
Is Supernus Pharmaceuticals' Long-Term Debt too high?
Supernus Pharmaceuticals' current Long-Term Debt is $0.0 Mil. Overall, Supernus Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Long-Term Debt compare to BCRX and PBH?
Supernus Pharmaceuticals' Long-Term Debt of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Supernus Pharmaceuticals's current Long-Term Debt is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $41.04, compared to a current price of $48.27 — trading 17.6% above its estimated fair value. The current Long-Term Debt is $0.0 Mil. Supernus Pharmaceuticals' overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Long-Term Debt is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued. The current stock price of $48.27 is trading 17.6% above its estimated GF Value™ of $41.04. GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for LTS:0LB2:

  • Long-Term Debt: $0.0 Mil
  • GF Value™: $41.04 vs. price of $48.27 (17.6% above fair value)
  • GF Score™: 88/100

No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supernus Pharmaceuticals Business Description

Other Exchanges SUPN:USAS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
88GF Score

Get the complete analysis for LTS:0LB2

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$48.27
Price
$41.04
GF Value